TAK
Takeda Pharmaceutical Co Ltd
17.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 35.4% | 35.9% | 28.9% | 26.3% | 22.0% | 19.3% | 21.0% | 19.7% | 17.2% | 16.9% | 17.7% | 20.0% | |
| 15.2% | 11.8% | 7.3% | 7.2% | 5.1% | 5.0% | 7.5% | 6.4% | 3.8% | 3.0% | 2.7% | 3.9% | |
| 16.6% | 14.6% | 8.6% | 9.1% | 5.2% | 5.1% | 7.8% | 6.6% | 4.0% | 3.1% | 2.8% | 3.9% | |
| 10.9% | 11.3% | 10.2% | 10.4% | 5.4% | 6.1% | 6.3% | 5.5% | 4.9% | 4.6% | 5.1% | 5.7% | |
| 6.1% | 6.6% | 5.2% | 5.2% | 7.1% | 5.9% | 5.8% | 6.5% | 7.1% | 8.0% | 8.5% | 9.0% | |
| 0.1% | 14.4% | 12.1% | 13.1% | 9.6% | 10.8% | 11.3% | 12.0% | 12.1% | 13.2% | 13.8% | – | |
| 19.1% | 20.4% | 23.5% | 25.1% | 30.0% | 31.3% | 31.2% | 33.4% | 34.3% | 35.8% | 37.4% | 37.6% | |
| 21.9% | 19.4% | 24.5% | 24.7% | 35.0% | 32.5% | 30.3% | 29.0% | 30.6% | 28.3% | 25.5% | 22.1% | |
| 48.6% | 47.4% | 55.3% | 50.9% | 62.8% | 63.1% | 59.9% | 56.9% | 54.5% | 51.9% | 51.3% | 49.7% | |
| 23.7% | 22.4% | 31.4% | 18.0% | 18.1% | 17.0% | 13.7% | 16.3% | 17.8% | 15.3% | 17.6% | 15.7% | |
| 2.3% | 6.0% | 12.5% | 0.0% | 7.1% | 4.6% | 0.2% | 1.5% | 2.4% | 2.4% | 3.9% | 3.3% | |
| 4.0% | 5.0% | 5.5% | 3.3% | 1.5% | 1.7% | 1.8% | 2.2% | 2.2% | 2.1% | 2.2% | 3.2% | |
| 0.1% | 0.0% | 13.8% | 24.0% | 34.4% | 35.1% | 35.7% | 31.4% | 29.0% | 29.6% | 27.8% | 28.2% | |
| 49.7% | 51.0% | 43.5% | 48.6% | 37.2% | 36.8% | 40.1% | 43.1% | 45.5% | 48.1% | 48.7% | 50.3% | |
| 37.3% | 39.8% | 34.7% | 37.9% | 11.3% | 10.7% | 11.7% | 11.2% | 11.0% | 9.2% | 8.3% | 6.8% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.